A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.

Lam WS, Creaney J, Chen FK, Chin WL, Muruganandan S, Arunachalam S, Attia MS, Read C, Murray K, Millward M, Spiro J, Chakera A, Gary Lee YC, Nowak AK.

Lung Cancer. 2020 Feb;140:87-92. doi: 10.1016/j.lungcan.2019.12.018. Epub 2019 Dec 31.

PMID: 31901768 IF 4.599